Level C· Early human research exploring benefitsProspective StudyPubMed

Extracellular matrix substrata alter adipocyte yield and lipogenesis in primary cultures of stromal-vascular cells from human adipose.

O'Connor KC., Song H., Rosenzweig N., Jansen DA.

Prospective Study, published in Biotechnol Lett (2003) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Biotechnol Lett (2003)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
14719807
DOI
10.1023/b:bile.0000004386.08923.ab
Citations
42

Abstract (original English)

The stromal-vascular fraction of human adipose was subjected to in vitro adipogenesis on different extracellular matrix substrata. Adipose tissue was harvested from the breast of 25 to 45 year-old female patients undergoing elective surgery. After 24 d, less than 5% of stromal-vascular cells had converted to adipocytes on fibronectin, 13% to 28% on tissue culture plastic and collagen I; and 59% +/- 7% on Matrigel. Lipid volume surpassed 4.5 x 10(3) microm3 cell(-1) for Matrigel and was 30% lower for the other substrata. Cell proliferation was evident for Matrigel and fibronectin, and cell spreading was most pronounced for fibronectin with a projected area exceeding 3 x 10(3) microm2 cell(-1). These results are relevant to the design of an adipose implant, providing insight into its feasibility and scaffold composition.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesAdultBreastCell Culture TechniquesCell DifferentiationCell DivisionCells, CulturedCollagenCollagen Type IDrug Combinations

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.